5 results on '"Blobner S"'
Search Results
2. Significance of molecular diagnostics for therapeutic decision-making in recurrent glioma.
- Author
-
Blobner J, Dengler L, Blobner S, Eberle C, Weller J, Teske N, Karschnia P, Rühlmann K, Heinrich K, Ziemann F, Greif PA, Jeremias I, Wuerstlein R, Hasselmann K, Dorostkar M, Harter PN, Quach S, Stoecklein V, Albert NL, Niyazi M, Tonn JC, Thon N, Christoph Westphalen B, and von Baumgarten L
- Abstract
Background: Targeted therapies have substantially improved survival in cancer patients with malignancies outside the brain. Whether in-depth analysis for molecular alterations may also offer therapeutic avenues in primary brain tumors remains unclear. We herein present our institutional experience for glioma patients discussed in our interdisciplinary molecular tumor board (MTB) implemented at the Comprehensive Cancer Center Munich (LMU)., Methods: We retrospectively searched the database of the MTB for all recurrent glioma patients after previous therapy. Recommendations were based on next-generation sequencing results of individual patient's tumor tissue. Clinical and molecular information, previous therapy regimens, and outcome parameters were collected., Results: Overall, 73 consecutive recurrent glioma patients were identified. In the median, advanced molecular testing was initiated with the third tumor recurrence. The median turnaround time between initiation of molecular profiling and MTB case discussion was 48 ± 75 days (range: 32-536 days). Targetable mutations were found for 50 recurrent glioma patients (68.5%). IDH1 mutation (27/73; 37%), epidermal growth factor receptor amplification (19/73; 26%), and NF1 mutation (8/73; 11%) were the most detected alterations and a molecular-based treatment recommendation could be made for all of them. Therapeutic recommendations were implemented in 12 cases (24%) and one-third of these heavily pretreated patients experienced clinical benefit with at least disease stabilization., Conclusions: In-depth molecular analysis of tumor tissue may guide targeted therapy also in brain tumor patients and considerable antitumor effects might be observed in selected cases. However, future studies to corroborate our results are needed., Competing Interests: Jens Blobner No disclosures. Laura Dengler No disclosures. Constantin Eberle No disclosures. Sven Blobner No disclosures. Jonathan Weller No disclosures. Nico Teske No disclosures. Philipp Karschnia No disclosures. Katharina Rühlmann No disclosures. Kathrin Heinrich No disclosures. Frank Ziemann No disclosures. Philipp A GreifNo disclosures. Irmela Jeremias No disclosures. Rachel Wuerstlein No disclosures. Korbinian Hasselmann No disclosures. Mario Dorostkar No disclosures. Patrick N Harter No disclosures. Stefanie Quach No disclosures. Veit Stöcklein No disclosures. Nathalie Lisa Albert No disclosures. Maximilian Niyazi No disclosures. Joerg-Christian Tonn Research grants from Novocure and Munich Surgical Imaging, honoraria for lectures from BrainLab and CarThera and royalties from Springer Publisher Intl. Niklas Thon Speaker honoraria from Novocure and BrainLab. Benedikt Christoph Westphalen No disclosures. Louisa von Baumgarten No disclosures., (© The Author(s) 2023. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology.)
- Published
- 2023
- Full Text
- View/download PDF
3. IgE type multiple myeloma exhibits hypermutated phenotype and tumor reactive T cells.
- Author
-
Kehl N, Kilian M, Michel J, Wagner TR, Uhrig S, Brobeil A, Sester LS, Blobner S, Steiger S, Hundemer M, Weinhold N, Rippe K, Fröhling S, Eichmüller SB, Bunse L, Müller-Tidow C, Goldschmidt H, Platten M, Raab MS, and Friedrich MJ
- Subjects
- DNA, Epitopes, Humans, Phenotype, T-Lymphocytes, Multiple Myeloma genetics
- Abstract
Multiple myeloma (MM) is a hematological malignancy originating from malignant and clonally expanding plasma cells. MM can be molecularly stratified, and its clonal evolution deciphered based on the Ig heavy and light chains of the respective malignant plasma cell clone. Of all MM subtypes, IgE type MM accounts for only <0.1% of cases and is associated with an aggressive clinical course and consequentially dismal prognosis. In such malignancies, adoptive transfer of autologous lymphocytes specifically targeting presented (neo)epitopes encoded by either somatically mutated or specifically overexpressed genes has resulted in substantial objective clinical regressions even in relapsed/refractory disease. However, there are no data on the genetic and immunological characteristics of this rare and aggressive entity. Here, we comprehensively profiled IgE type kappa MM on a genomic and immune repertoire level by integrating DNA- and single-cell RNA sequencing and comparative profiling against non-IgE type MM samples. We demonstrate distinct pathophysiological mechanisms as well as novel opportunities for targeting IgE type MM. Our data further provides the rationale for patient-individualized neoepitope-targeting cell therapy in high tumor mutation burden MM., Competing Interests: Competing interests: None declared., (© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2022
- Full Text
- View/download PDF
4. Proimmunogenic impact of MEK inhibition synergizes with agonist anti-CD40 immunostimulatory antibodies in tumor therapy.
- Author
-
Baumann D, Hägele T, Mochayedi J, Drebant J, Vent C, Blobner S, Noll JH, Nickel I, Schumacher C, Boos SL, Daniel AS, Wendler S, Volkmar M, Strobel O, and Offringa R
- Subjects
- Animals, Antibodies, Monoclonal therapeutic use, Antineoplastic Combined Chemotherapy Protocols chemistry, Antineoplastic Combined Chemotherapy Protocols therapeutic use, Biomarkers, Pharmacological metabolism, CD40 Antigens immunology, Cell Line, Tumor, Cell Proliferation drug effects, Cell Survival drug effects, Dendritic Cells immunology, Dendritic Cells metabolism, Drug Synergism, Gene Expression Profiling, Humans, Macrophages drug effects, Macrophages immunology, Male, Mice, Mice, Inbred C57BL, Protein Kinase Inhibitors chemistry, Protein Kinase Inhibitors therapeutic use, T-Lymphocytes drug effects, T-Lymphocytes immunology, T-Lymphocytes metabolism, Transcriptome genetics, Adenocarcinoma drug therapy, Antibodies, Monoclonal pharmacology, Antineoplastic Combined Chemotherapy Protocols pharmacology, CD40 Antigens agonists, Carcinoma, Pancreatic Ductal drug therapy, Mitogen-Activated Protein Kinase Kinases antagonists & inhibitors, Protein Kinase Inhibitors pharmacology
- Abstract
Cancer types with lower mutational load and a non-permissive tumor microenvironment are intrinsically resistant to immune checkpoint blockade. While the combination of cytostatic drugs and immunostimulatory antibodies constitutes an attractive concept for overcoming this refractoriness, suppression of immune cell function by cytostatic drugs may limit therapeutic efficacy. Here we show that targeted inhibition of mitogen-activated protein kinase (MAPK) kinase (MEK) does not impair dendritic cell-mediated T cell priming and activation. Accordingly, combining MEK inhibitors (MEKi) with agonist antibodies (Abs) targeting the immunostimulatory CD40 receptor results in potent synergistic antitumor efficacy. Detailed analysis of the mechanism of action of MEKi shows that this drug exerts multiple pro-immunogenic effects, including the suppression of M2-type macrophages, myeloid derived suppressor cells and T-regulatory cells. The combination of MEK inhibition with agonist anti-CD40 Ab is therefore a promising therapeutic concept, especially for the treatment of mutant Kras-driven tumors such as pancreatic ductal adenocarcinoma.
- Published
- 2020
- Full Text
- View/download PDF
5. Peripheral tissues reprogram CD8+ T cells for pathogenicity during graft-versus-host disease.
- Author
-
Santos E Sousa P, Ciré S, Conlan T, Jardine L, Tkacz C, Ferrer IR, Lomas C, Ward S, West H, Dertschnig S, Blobner S, Means TK, Henderson S, Kaplan DH, Collin M, Plagnol V, Bennett CL, and Chakraverty R
- Subjects
- Animals, Antigens, CD genetics, Antigens, CD metabolism, Antigens, Surface genetics, Antigens, Surface metabolism, Bone Marrow Transplantation adverse effects, Cells, Cultured, Cellular Reprogramming genetics, Disease Models, Animal, Female, Gene Expression Regulation immunology, Graft vs Host Disease pathology, Hematopoietic Stem Cell Transplantation adverse effects, Humans, Langerhans Cells metabolism, Lectins, C-Type genetics, Lectins, C-Type metabolism, Male, Mannose-Binding Lectins genetics, Mannose-Binding Lectins metabolism, Mice, Mice, Inbred C57BL, Mice, Transgenic, Multigene Family genetics, Multigene Family immunology, Primary Cell Culture, Receptors, Notch metabolism, Skin cytology, Skin pathology, T-Lymphocytes, Cytotoxic metabolism, Transplantation Chimera, Transplantation, Homologous adverse effects, Cellular Reprogramming immunology, Graft vs Host Disease immunology, Langerhans Cells immunology, Skin immunology, T-Lymphocytes, Cytotoxic immunology
- Abstract
Graft-versus-host disease (GVHD) is a life-threatening complication of allogeneic stem cell transplantation induced by the influx of donor-derived effector T cells (TE) into peripheral tissues. Current treatment strategies rely on targeting systemic T cells; however, the precise location and nature of instructions that program TE to become pathogenic and trigger injury are unknown. We therefore used weighted gene coexpression network analysis to construct an unbiased spatial map of TE differentiation during the evolution of GVHD and identified wide variation in effector programs in mice and humans according to location. Idiosyncrasy of effector programming in affected organs did not result from variation in T cell receptor repertoire or the selection of optimally activated TE. Instead, TE were reprogrammed by tissue-autonomous mechanisms in target organs for site-specific proinflammatory functions that were highly divergent from those primed in lymph nodes. In the skin, we combined the correlation-based network with a module-based differential expression analysis and showed that Langerhans cells provided in situ instructions for a Notch-dependent T cell gene cluster critical for triggering local injury. Thus, the principal determinant of TE pathogenicity in GVHD is the final destination, highlighting the need for target organ-specific approaches to block immunopathology while avoiding global immune suppression.
- Published
- 2018
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.